Literature DB >> 2201730

Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone.

J Mouret1, D Ruel, F Maillard, M Bianchi.   

Abstract

This double-blind study was performed on 10 aged insomniac patients who received, during 15 days, either triazolam (0.25 mg) or zopiclone (7.5 mg) at bed time. This in-patient period was bounded by two ambulatory periods of 5 days each, and two in-patient periods of 3 days each, during which the patients received a placebo tablet at bed time. Thirteen sleep recordings per patient were performed before (3 nights), upon initiation of active treatment (3 nights), at the end of the active treatment period (3 nights) and during the following 3 "withdrawal" nights. A clear improvement of sleep patterns was observed with both drugs, although opposite effects on delta sleep were observed, namely a decrease with triazolam and an increase with zopiclone. A carry-over effect of the enhancement of delta sleep by zopiclone took place during the first 3 withdrawal nights. As is well known, sleep problems become increasingly common with age. Epidemiological studies show that although they only represent 11% of the population. Americans over 60 years old are prescribed about 40% of sleeping pills (Mendelson, 1980). Disturbed sleep in this population is often associated with medical disorders or induced by drugs like beta-adrenergic blockers. It must be admitted, however, that, possibly due to the association with medical or situational problems there have been only few attempts to assess the efficiency of hypnotic drugs in elderly insomniac patients. These are the reasons why in this study the effectiveness of zopiclone was compared to that of triazolam in insomniac patients aged over 60 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201730

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  14 in total

Review 1.  Management of insomnia and long-term use of sedative-hypnotic drugs in older patients.

Authors:  Jacqueline M McMillan; Elizabeth Aitken; Jayna M Holroyd-Leduc
Journal:  CMAJ       Date:  2013-09-23       Impact factor: 8.262

Review 2.  Polysomnographic effects of hypnotic drugs. A review.

Authors:  L Parrino; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

3.  [Sleep, respiration and benzodiazepines: effects of benzodiazepines on nocturnal respiration].

Authors:  P Lemoine
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

Review 4.  Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

Authors:  Jennifer Glass; Krista L Lanctôt; Nathan Herrmann; Beth A Sproule; Usoa E Busto
Journal:  BMJ       Date:  2005-11-11

Review 5.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

6.  Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.

Authors:  Børge Sivertsen; Siri Omvik; Ståle Pallesen; Inger Hilde Nordhus; Bjørn Bjorvatn
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

Review 7.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 8.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 9.  Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?

Authors:  Christian Dolder; Michael Nelson; Jonathan McKinsey
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.